Key result
New oral anticoagulants, including direct thrombin and factor Xa inhibitors, provide alternatives to traditional anticoagulants for preventing and treating venous thromboembolism.
Why the study?
Do new oral anticoagulants improve the prevention and treatment of venous thromboembolism compared to traditional anticoagulants?
Do new oral anticoagulants improve the prevention and treatment of venous thromboembolism compared to traditional anticoagulants?
Newer oral anticoagulants offer practical alternatives to traditional agents for VTE management by eliminating the need for parenteral administration and routine laboratory monitoring.
Traditional anticoagulants, such as warfarin and enoxaparin, have several limitations, including parenteral administration, need for laboratory monitoring, and ongoing dose adjustment, which may limit optimal patient care. Newer oral anticoagulants, such as direct thrombin inhibitors (e.g., dabigatran etexilate) and direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban), have been developed to overcome these drawbacks, and thereby improve patient care. Several of these agents have been approved for use in the prevention and treatment of venous and/or systemic thromboembolism. The objective of this paper is to provide an overview of the available clinical trial data for these new oral anticoagulants in the prevention and treatment of venous thromboembolism and a practical update for clinicians.
No takes yet. Share an insight, caveat, or question.
Tun et al. (2013) conducted a review in Venous thromboembolism. New oral anticoagulants (direct thrombin inhibitors and direct factor Xa inhibitors) vs. Traditional anticoagulants (warfarin and enoxaparin) was evaluated. New oral anticoagulants, including direct thrombin and factor Xa inhibitors, provide alternatives to traditional anticoagulants for preventing and treating venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: